ERNA ETERNA THERAPEUTICS INC.

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Access the “What This Means” segment 

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a .

As part of the segment, Sanjeev Luther, President and CEO of Ernexa, discussed the Company’s with Cellipont Bioservices focused on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa's lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.

The Virtual Investor “What This Means” segment featuring Ernexa can be accessed .

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

For more information, visit .

Media Contact

Sharon Golubchik

RAYNZ

Investor Contact

Jenene Thomas

JTC Team, LLC

(908) 824-0775



EN
06/11/2025

Underlying

ERNAETERNA THERAPEUTICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ETERNA THERAPEUTICS INC.

 PRESS RELEASE
Free
ERNA ETERNA THERAPEU...

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Se...

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET Register CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that of Ernexa, will participate in the on Wednesday, February 25, 2026, at 4:00 PM ET. As part of the segment, of Ernexa, will provide a corporate overview and...

February 20, 2026 1 EN
 PRESS RELEASE
Free
ERNA ETERNA THERAPEU...

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 21,000,000 shares of common stock, at a combined public offering price of $0.50 per share (or per common stock equiv...

February 6, 2026 1 EN
 PRESS RELEASE
Free
ERNA ETERNA THERAPEU...

Ernexa Therapeutics Participates in Virtual Investor “What This Means”...

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA Access the “What This Means” segment  CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a discussing the Company’s recent successful Pre-IND meeting with the U.S. Food and Drug Administration and its continued advancement toward a first-in-human trial for ovarian cancer...

February 3, 2026 1 EN
 PRESS RELEASE
Free
ERNA ETERNA THERAPEU...

Ernexa Therapeutics Selected as One of Only Ten Global Companies for P...

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it has been selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program (JEAP), a highly competitive initiative launched by the Japan External Trade Organization (JETRO). JEAP drew approximately 70 regenerative medicine companies f...

January 27, 2026 1 EN
 PRESS RELEASE
Free
ERNA ETERNA THERAPEU...

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Conti...

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readiness Company on track to initiate first-in-human (FIH) trial for the treatment of ovarian cancer in the second half of 2026 CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the successful completion of its r...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch